Biotech: Page 9
-
Permission granted by City of Hope
A ‘widening gap’ in access to new cancer meds drives efforts from City of Hope and Bristol Myers
Cancer care is improving so quickly that receiving newer medications can be difficult — City of Hope’s wide oncology network and a 10-year commitment from Bristol Myers Squibb offer some solutions.
By Michael Gibney • June 6, 2024 -
Permission granted by FibroBiologics
Biotech SpotlightRegenerative cell therapy biotech uses IPO to blast into human trials
Bucking conventional fundraising, FibroBiologics’ CEO Pete O’Heeron explains why the biotech company bet on themselves in the public market.
By Amy Baxter • June 5, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Courtesy of Merck & Co.
Merck and Moderna’s cancer vaccine snags a clinical win in a field decades old
Cancer vaccines are taking off in the clinic, and a partnership between Merck and Moderna is at the forefront of a new wave of immunotherapy.
By Michael Gibney • June 3, 2024 -
Stock via Getty Images
Q&AIn an era of big patent losses, drug launches need years of runway
Jim Lang, CEO of Eversana, explains the shifting commercial environment and how past drug launch failures are informing the future.
By Amy Baxter • June 3, 2024 -
Justin Sullivan via Getty Images
After two Big Pharma deals, Nimbus looks to keep the hits coming
With the billion-dollar-plus deals under its belt with Gilead and Takeda, the biotech’s CEO explains where the company is going next.
By Kelly Bilodeau • June 3, 2024 -
Stock via Getty Images
Deadline looms for Chinese biotech contracts
The latest version of The Biosecure Act working its way through Congress could make waves in the U.S. biotech industry.
By Amy Baxter • May 31, 2024 -
Stock via Getty Images
Biotech SpotlightMythic Therapeutics aims to overcome one of ADC’s long-standing challenges
By developing ADCs that bind more directly to the target, Mythic Therapeutics believes its technology could deliver a step change for efficacy and safety.
By Alexandra Pecci • May 30, 2024 -
Getty Images via Getty Images
Can robots break the cell therapy bottleneck?
A partnership between the cell therapy delivery specialist Portal Biotechnologies and precision robotics maker Multiply Labs could bring the manufacturing bottleneck under control, the CEOs said.
By Michael Gibney • May 29, 2024 -
Stock via Getty Images
Where competition is heating up in pharma
The stage is set for potential blockbuster-level showdowns targeting these three indications.
By Meagan Parrish • May 24, 2024 -
Dan Kitwood/Getty Images via Getty Images
AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets
Promises made by pharma and biotech companies show confidence in the future of their business and dedication to financial success, R&D and environmental protection.
By Michael Gibney • May 23, 2024 -
Stock via Getty Images
3 up-and-coming US biotech hotspots
These three U.S. cities are putting themselves on the biotech map as unsung hubs of the industry.
By Alexandra Pecci • May 21, 2024 -
Sean Gallup via Getty Images
Execs from Bayer, Kite and Orca sound off on their launch strategies for cell and gene therapies
Planning early, staying nimble and approaching commercialization as a team sport should be top priorities, the leaders said.
By Amy Baxter • May 20, 2024 -
Leon Neal / Getty Images via Getty Images
Why AlphaFold 3 is stirring up so much buzz in pharma
The “Nobel Prize-worthy invention” could be worth hundreds of billions commercially — and have a deep impact on drug R&D.
By Kelly Bilodeau • May 20, 2024 -
shutterstock.com/Sergey Nivens
Sponsored by BioLineRxFlipping a biotech incubator into a commercial company
How persistence led to BioLineRx’s first approved therapy and promising pipeline.
May 20, 2024 -
iStock via Getty Images
Investors put $400M into biotech licensing obesity drugs from China
The biotech, tentatively named Hercules CM Newco, has rights to three incretin drugs discovered by Jiangsu Hengrui Pharmaceuticals, two of which are in clinical testing.
By Gwendolyn Wu • May 16, 2024 -
Courtesy of Eli Lilly
Big Pharma’s most improved drugs: a new generation of blockbusters
The old guard of pharma bestsellers is seeing more competition, but newer drugs demonstrating sales and revenue growth can build up the coffers in years to come.
By Michael Gibney • May 14, 2024 -
jetcityimage via Getty Images
Lilly’s donanemab will face an Alzheimer’s adcomm in June, setting the stage for a Leqembi showdown
The FDA announced a June advisory committee date, potentially introducing a new Alzheimer’s treatment to compete with Eisai and Biogen’s Leqembi.
By Michael Gibney • May 9, 2024 -
Stock via Getty Images
Using the body as ‘a bioreactor’ — a regenerative medicine expert on where the field is headed
The director of the University of Pittsburgh’s McGowan Institute for Regenerative Medicine believes the industry is “turning a corner.”
By Alexandra Pecci • May 7, 2024 -
Carsten Koall via Getty Images
Takeover target? Activist investor believes Novavax tech would be in ‘better hands’ with Big Pharma
With its next earnings report looming, pushback from an investor is adding pressure on Novavax to boost performance.
By Meagan Parrish • May 3, 2024 -
iStock via Getty Images
$4M+ gene therapies? How payers can adapt to a new reality of pricey ‘cures’
Pricey gene therapies promise great benefit to patients but pose a threat to the payer landscape — ICER and a Tufts think tank are offering potential solutions.
By Michael Gibney • May 2, 2024 -
Sarah Silbiger via Getty Images
As AI proliferates in pharma, regulators look to catch up in clinical trials
The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance.
By Amy Baxter • May 1, 2024 -
Courtesy of Vertex Pharmaceuticals
ProfileNow a biopharma powerhouse, Vertex’s R&D bedrock could deliver tomorrow’s blockbusters
From its landmark CRISPR approval to its potential breakthrough drug for pain, Vertex’s development approach, led by chief scientific officer Dr. David Altshuler, is paying off.
By Michael Gibney • April 30, 2024 -
Stock via Getty Images
4 offbeat biotechs making a splash in the life sciences
From resurrecting an extinct species to improving regenerative medicines with plant-based materials, these biotechs are on the leading edge of science.
By Alexandra Pecci • April 30, 2024 -
Drew Angerer via Getty Images
As BMS announces major cuts, its Karuna deal looks poised to drive growth
The company's schizophrenia drug picked up in its $14 billion acquisition of Karuna Therapeutics recently generated positive long-term data from its phase 3 program.
By Kelly Bilodeau • April 29, 2024 -
Courtesy of Alltrna
Q&AHow a biotech exec is leveraging Big Pharma lessons to advance tRNA
Michelle Werner shares how the lessons from her resume — and personal experience — are driving her work with novel therapeutics.
By Amy Baxter • April 29, 2024
Previous
